Structural studies on human rhinovirus 14 drug-resistant compensation mutants.
Hadfield, A.T., Oliveira, M.A., Kim, K.H., Minor, I., Kremer, M.J., Heinz, B.A., Shepard, D., Pevear, D.C., Rueckert, R.R., Rossmann, M.G.(1995) J Mol Biol 253: 61-73
- PubMed: 7473717 Search on PubMed
- DOI: 10.1006/jmbi.1995.0536
- Primary Citation of Related Structures:  
1RUJ, 1RUI, 1RUH, 1RUG, 1RUF, 1RUE, 1RUD, 1RUC - PubMed Abstract: 
- Win 52035-2 Inhibits Both Attachment and Eclipse of Human Rhinovirus 14
Shepard, D.A., Heinz, B.A., Rueckert, R.R.
(1993) J Virol 67: 2245 - Analysis of the Structure of a Common Cold Virus, Human Rhinovirus 14, Refined at a Resolution of 3.0 Angstroms
Arnold, E., Rossmann, M.G.
(1990) J Mol Biol 211: 763 - Three Dimensional Structures of Drug-Resistant Mutants of Human Rhinovirus 14
Badger, J., Krishnaswamy, S., Kremer, M.J., Oliveira, M.A., Rossmann, M.G., Heinz, B.A., Rueckert, R.R., Dutko, F.J., Mckinlay, M.A.
(1989) J Mol Biol 207: 163 - Structural Analysis of Antiviral Agents that Interact with the Capsid of Human Rhinoviruses
Badger, J., Minor, I., Oliveira, M.A., Smith, T.J., Rossmann, M.G.
(1989) Proteins 6: 1 - Genetics and Molecular Basis for Resistance of Human Rhinovirus 14 to an Antiviral Drug
Heinz, B.A., Rueckert, R.R., Shepard, D.A., Dutko, F.J., Mckinlay, M.A., Fancher, M., Rossmann, M.G., Badger, J., Smith, T.J.
(1989) J Virol 63: 2476 - The Use of Molecular Replacement Phases for the Refinement of the Human Rhinovirus 14 Structure
Arnold, E., Rossmann, M.G.
(1988) Acta Crystallogr A 44: 270 - Structural Analysis of a Series of Antiviral Agents Complexed with Human Rhinovirus 14
Badger, J., Minor, I., Kremer, M.J., Oliveira, M.A., Smith, T.J., Griffith, J.P., Guerin, D.M.A., Krishnaswamy, S., Luo, M., Rossmann, M.G., Mckinlay, M.A., Diana, G.D., Dutko, F.J., Fancher, M., Rueckert, R.R., Heinz, B.A.
(1988) Proc Natl Acad Sci U S A 85: 3304 - The Structure Determination of a Common Cold Virus, Human Rhinovirus 14
Arnold, E., Vriend, G., Luo, M., Griffith, J.P., Kamer, G., Erickson, J.W., Johnson, J.E., Rossmann, M.G.
(1987) Acta Crystallogr A 43: 346 - The Site of Attachment in Human Rhinovirus 14 for Antiviral Agents that Inhibit Uncoating
Smith, T.J., Kremer, M.J., Luo, M., Vriend, G., Arnold, E., Kamer, G., Rossmann, M.G., Mckinlay, M.A., Diana, G.D., Otto, M.J.
(1986) Science 233: 1286 - Structure of a Human Common Cold Virus and Functional Relationship to Other Picornaviruses
Rossmann, M.G., Arnold, E., Erickson, J.W., Frankenberger, E.A., Griffith, J.P., Hecht, H.-J., Johnson, J.E., Kamer, G., Luo, M., Mosser, A.G., Rueckert, R.R., Sherry, B., Vriend, G.
(1985) Nature 317: 145 - Virion Orientation in Cubic Crystals of the Human Common Cold Virus Hrv14
Arnold, E., Erickson, J.W., Fout, G.S., Frankenberger, E.A., Hecht, H.-J., Luo, M., Rossmann, M.G., Rueckert, R.R.
(1984) J Mol Biol 177: 417
Structures have been determined of three human rhinovirus 14 (HRV14) compensation mutants that have resistance to the antiviral capsid binding compounds WIN 52035 and WIN 52084. In addition, the structure of HRV14 is reported, with a site-directed mutati ...
Structures have been determined of three human rhinovirus 14 (HRV14) compensation mutants that have resistance to the antiviral capsid binding compounds WIN 52035 and WIN 52084. In addition, the structure of HRV14 is reported, with a site-directed mutation at residue 1219 in VP1. A spontaneous mutation occurs at the same site in one of the compensation mutants. Some of the mutations are on the viral surface in the canyon and some lie within the hydrophobic binding pocket in VP1 below the ICAM footprint. Those mutant virus strains with mutations on the surface bind better to cells than does wild-type virus. The antiviral compounds bind to the mutant viruses in a manner similar to their binding to wild-type virus. The receptor and WIN compound binding sites overlap, causing competition between receptor attachment and antiviral compound binding. The compensation mutants probably function by shifting the equilibrium in favor of receptor binding. The mutations in the canyon increase the affinity of the virus for the receptor, while the mutations in the pocket probably decrease the affinity of the WIN compounds for the virus by reducing favorable hydrophobic contacts and constricting the pore through which the antiviral compounds are thought to enter the pocket. This is in contrast to the resistant exclusion mutants that block compounds from binding by increasing the bulk of residues within the hydrophobic pocket in VP1.
Related Citations: 
Organizational Affiliation: 
Department of Biological Sciences, Purdue University, West Lafayette, IN 47907-1392, USA.